{"id":71409,"date":"2026-05-20T09:18:16","date_gmt":"2026-05-20T09:18:16","guid":{"rendered":"https:\/\/medsbase.com\/l-carnitine\/"},"modified":"2026-10-15T10:33:57","modified_gmt":"2026-10-15T10:33:57","slug":"l-carnitine","status":"publish","type":"product","link":"https:\/\/medsbase.com\/it\/product\/l-carnitine\/","title":{"rendered":"L-Carnitina (Levocarnitina)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Risposta rapida \u2014 Cos'\u00e8 la L-Carnitina?<\/h3>\n<p style=\"margin: 0;\"><strong>L-Carnitina<\/strong> (levocarnitina; (3R)-3-idrossi-4-(trimetilammonio)butanoato) \u00e8 un piccolo derivato amminoacidico di ammonio quaternario \u2014 <em>non un peptide<\/em> \u2014 that functions as the essential carrier molecule for transporting long-chain fatty acids across the mitochondrial inner membrane for \u03b2-oxidation. It is endogenously biosynthesised from L-lysine and L-methionine and is concentrated in skeletal muscle, heart, and liver. L-Carnitine is studied across mitochondrial-function studies, fat-oxidation physiology, insulin-sensitivity models, cardiovascular studies, neuroprotection (Alzheimer \/ autism in-vitro work), exercise physiology, and sperm-motility studies. Supplied in 600 mg and 1200 mg vials as levocarnitine USP-grade zwitterion for clinical studies use only. Stocked in our peptide catalogue alongside <a href=\"https:\/\/medsbase.com\/it\/nad\/\">NAD\u207a<\/a> as a complementary mitochondrial \/ metabolic support-injectable.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Cosa ottieni con MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/it\/reviews\/\">recensioni dei clienti<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Ogni ordine \u00e8 coperto dalla nostra <a href=\"https:\/\/medsbase.com\/it\/medsbase-re-shipment-assurance-policy\/\"><strong>Politica di Garanzia di Rispedizione<\/strong><\/a> \u2014 se il tuo pacco non arriva entro 20 giorni lavorativi, lo rispediamo.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Specifiche<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Dettaglio<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Numero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">541-15-1 (sale interno della L-carnitina \/ zwitterione)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Tipo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Derivato amminoacidico di ammonio quaternario (<em>non un peptide<\/em>); l'enantiomero levo-rotatorio (3R) \u00e8 la forma biologicamente attiva responsabile del trasporto mitocondriale degli acidi grassi a catena lunga tramite il sistema carnitina palmitoiltransferasi (CPT-I \/ CPT-II); biosintetizzato endogenamente da L-lisina e L-metionina; chiamato anche levocarnitina (INN) o Vitamina B<sub>T<\/sub> nella letteratura pi\u00f9 vecchia<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Formula Molecolare<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>7<\/sub>H<sub>15<\/sub>NO<sub>3<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso molecolare<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">161.20 g\/mol<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Nome IUPAC<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">(3R)-3-idrossi-4-(trimetilazaniumil)butanoato<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Sequenza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">n\/d (derivato amminoacidico a piccola molecola \u2014 non un peptide)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Polvere liofilizzata, da bianca a biancastra (forma zwitterionica \/ sale interno)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Purezza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificato con HPLC, COA disponibile su richiesta)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Conservazione<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizzato: 2\u20138 \u00b0C (frigorifero) per stock di lavoro a breve termine; \u221220 \u00b0C per lo stoccaggio a lungo termine di flaconi non aperti. Ricostituito: 2\u20138 \u00b0C, utilizzare entro ~30 giorni. Proteggere dalla luce. Evitare ripetuti cicli di congelamento-scongelamento della soluzione ricostituita. La levocarnitina \u00e8 igroscopica \u2014 richiudere prontamente i flaconi dopo ogni prelievo.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilit\u00e0<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Altamente solubile in acqua (zwitterione a pH fisiologico). Si ricostituisce rapidamente in acqua batteriostatica o acqua sterile con leggera agitazione. Non sono necessari solventi specializzati. Le soluzioni di lavoro possono essere preparate a concentrazioni fino a ~500 mg\/mL senza precipitazione.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Cos'\u00e8 la L-Carnitina?<\/h2>\n<p><strong>L-Carnitina<\/strong> (levocarnitina) \u00e8 un piccolo derivato aminoacidico quaternario di ammonio, solubile in acqua, con formula molecolare C<sub>7<\/sub>H<sub>15<\/sub>NO<sub>3<\/sub> e peso molecolare 161,20 g\/mol. \u00c8 <em>non un peptide<\/em> \u2014 it is a single-residue zwitterionic molecule derived metabolically from the amino acids L-lysine and L-methionine through a multistep biosynthetic pathway distributed across kidney, liver, and brain. Only the (3R) enantiomer (the L-form \/ levo form \/ levocarnitine) is biologically active; the (3S) enantiomer (D-carnitine) is inactive and is now well-documented to interfere with the L-form&#8217;s transport, which is why pharmaceutical-grade material is supplied as the enantiomerically pure L-form rather than as racemic DL-carnitine. The molecule&#8217;s central physiological function is to serve as the <strong>vettore obbligato<\/strong> per il trasporto degli acidi grassi a catena lunga (C<sub>12<\/sub>+) across the otherwise-impermeable mitochondrial inner membrane, where they are subsequently broken down by \u03b2-oxidation to acetyl-CoA, the substrate for the citric acid cycle and ATP synthesis. The transport machinery \u2014 carnitine palmitoyltransferase I (CPT-I) on the outer mitochondrial membrane, the carnitine\/acylcarnitine translocase (CACT) across the inner membrane, and carnitine palmitoyltransferase II (CPT-II) on the matrix side \u2014 converts free fatty acids into acylcarnitines, ferries them across the bilayer, and releases them again as acyl-CoAs for oxidation. L-Carnitine is therefore the rate-limiting metabolite for fat oxidation in tissues with high oxidative demand: skeletal muscle, cardiac muscle, and liver. L-Carnitine is also a high-affinity buffer of the cellular acyl-CoA \/ free-CoA ratio. By accepting acyl groups onto its hydroxyl side chain, L-carnitine maintains the intracellular pool of free CoA that other CoA-dependent enzymes (pyruvate dehydrogenase, \u03b1-ketoglutarate dehydrogenase, fatty-acid \u03b2-oxidation) require to function. Carnitine deficiency therefore produces effects beyond fat oxidation alone \u2014 propagating into pyruvate handling, TCA-cycle flux, and overall mitochondrial bioenergetic balance. L-Carnitine has FDA approval (under the name <em>levocarnitina<\/em>) per uso terapeutico umano in <strong>carenza primaria e secondaria di carnitina<\/strong> (oral and IV formulations) and is widely used in contexts that examine mitochondrial bioenergetics, fat oxidation, insulin sensitivity, cardiovascular function, neuroprotection, exercise physiology, and sperm motility. <\/p>\n<h2>Meccanismo d'azione \u2014 Trasporto mitocondriale degli acidi grassi a catena lunga<\/h2>\n<p>L-Carnitine&#8217;s central mechanism is documented across several decades of mitochondrial biochemistry studies:<\/p>\n<ul>\n<li><strong>Carnitina palmitoiltransferasi I (CPT-I) \u2014 membrana mitocondriale esterna<\/strong> \u2014 Gli acidi grassi a catena lunga si attivano prima in acil-CoA a catena lunga nel citoplasma. La CPT-I, incorporata nella membrana mitocondriale esterna, trasferisce il gruppo acile dal CoA sull'idrossile della L-carnitina, generando acilcarnitina a catena lunga. Questo \u00e8 il passaggio impegnativo e pi\u00f9 regolato dell'ossidazione dei grassi mitocondriali \u2014 la CPT-I \u00e8 inibita allostericamente dal malonil-CoA (il prodotto dell'acetil-CoA carbossilasi nel metabolismo lipogenico in stato di saziet\u00e0), che \u00e8 il modo in cui l'insulina \/ glucagone e il sistema AMPK regolano l'ossidazione dei grassi rispetto alla sintesi dei grassi.<\/li>\n<li><strong>Carnitina\/acilcarnitina translocasi (CACT) \u2014 membrana mitocondriale interna<\/strong> \u2014 L'acilcarnitina a catena lunga generata dalla CPT-I non pu\u00f2 diffondere attraverso la membrana mitocondriale interna. La CACT, un antiporto, scambia l'acilcarnitina citosolica con la carnitina libera nella matrice in una stechiometria 1:1, consegnando l'acilcarnitina nella matrice e riciclando la carnitina per ulteriori cicli di CPT-I.<\/li>\n<li><strong>Carnitina palmitoiltransferasi II (CPT-II) \u2014 membrana mitocondriale interna, rivolta verso la matrice<\/strong> \u2014 Nella matrice, la CPT-II inverte la reazione della CPT-I: trasferisce il gruppo acile dalla carnitina di nuovo sul CoA della matrice, rigenerando l'acil-CoA a catena lunga, che ora pu\u00f2 entrare nella \u03b2-ossidazione. La carnitina libera rilasciata viene restituita attraverso la membrana tramite la CACT per un altro ciclo di trasporto.<\/li>\n<li><strong>Tamponamento del rapporto Acyl-CoA \/ CoA libera e flessibilit\u00e0 metabolica<\/strong> \u2014 Oltre al sistema di trasporto a catena lunga, la L-carnitina accetta gruppi acilici a catena corta e media (acetilcarnitina, propionilcarnitina) e agisce come un tampone ad alta capacit\u00e0 del rapporto intracellulare acil-CoA \/ CoA libero. Ci\u00f2 mantiene il CoA libero per la piruvato deidrogenasi, l'\u03b1-chetoglutarato deidrogenasi e la \u03b2-ossidazione. La generazione di acetilcarnitina funge anche da meccanismo attraverso il quale l'eccesso di acetil-CoA \u2014 derivante dal digiuno, dalla chetogenesi o dall'esercizio fisico \u2014 pu\u00f2 essere tamponato in sicurezza ed esportato attraverso la membrana mitocondriale.<\/li>\n<\/ul>\n<p>The pharmacokinetic profile of orally-administered L-carnitine is unusual: oral bioavailability is low (~15%) due to active intestinal saturation, with the remaining 85% subject to extensive bacterial degradation in the colon (yielding TMA and TMAO \u2014 a finding that has attracted attention in cardiovascular studies). Intravenous and intramuscular administration routes achieve much higher plasma levels and bypass the gut-microbial degradation pathway entirely, which is why pharmacological protocols commonly use parenteral administration despite the convenience of oral dosing. <\/p>\n<h2>Published Evidence<\/h2>\n<p>L-Carnitine is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Funzione mitocondriale e bioenergetica<\/strong> \u2014 Respirometria Seahorse \/ Oroboros, potenziale di membrana mitocondriale, tasso di generazione di ATP, tasso di ossidazione degli acidi grassi in colture primarie di epatociti, muscolo scheletrico e cardiomiociti<\/li>\n<li><strong>Ossidazione dei grassi e flessibilit\u00e0 metabolica<\/strong> \u2014 transizione tra l'ossidazione di glucosio e grassi nel muscolo scheletrico e nel fegato; modelli di inversione della resistenza all'insulina; coorti di studio su roditori obesi e DIO<\/li>\n<li><strong>Insulin sensitivity studies<\/strong> \u2014 improvement in skeletal-muscle insulin sensitivity in models of metabolic syndrome and type 2 diabetes preclinical studies; mechanistic dissection of the L-carnitine \/ acyl-CoA buffering \/ pyruvate handling axis<\/li>\n<li><strong>Cardiovascular studies<\/strong> \u2014 angina, heart failure, ischemia-reperfusion injury, cardiomyopathy (in particular doxorubicin-induced cardiotoxicity and primary carnitine-deficiency cardiomyopathy); TMA\/TMAO microbiome-axis cardiovascular studies<\/li>\n<li><strong>Neuroprotection studies<\/strong> \u2014 Alzheimer-disease in-vitro models (acetylcarnitine specifically), Parkinson-disease models, peripheral diabetic neuropathy preclinical models, autism-spectrum studies where carnitine deficiency has been implicated<\/li>\n<li><strong>Sperm motility and male fertility studies<\/strong> \u2014 epididymal acquisition of motility, mitochondrial energetics of sperm flagellar beat, antioxidant protection of spermatozoa; one of the most-studied compounds in male-fertility studies<\/li>\n<li><strong>Exercise physiology and endurance studies<\/strong> \u2014 substrate utilisation during prolonged exercise, glycogen sparing, post-exercise recovery; studies interest in carnitine loading protocols and insulin co-administration to overcome muscle-uptake saturation<\/li>\n<li><strong>Chronic kidney disease \/ haemodialysis studies<\/strong> \u2014 carnitine deficiency is common in dialysis-dependent end-stage renal disease patients and L-carnitine has FDA approval for this indication; preclinical studies continues on dialysis-related cardiomyopathy and muscle weakness<\/li>\n<\/ul>\n<p>For broader context on mitochondrial and metabolic-axis compounds in this catalogue, see <a href=\"https:\/\/medsbase.com\/it\/nad\/\">NAD\u207a<\/a> (coenzima dinucleotide ossidato, substrato centrale del trasporto di elettroni), <a href=\"https:\/\/medsbase.com\/it\/ss-31-elamipretide\/\">SS-31 (Elamipretide)<\/a> (peptide legante la cardiolipina mirato ai mitocondri), e <a href=\"https:\/\/medsbase.com\/it\/mots-c\/\">MOTS-c<\/a> (peptide regolatore metabolico derivato dai mitocondri). Esplora l'intera <a href=\"https:\/\/medsbase.com\/it\/peptides\/\">peptides &amp; compounds catalog<\/a> per composti correlati. <\/p>\n<h2>Concentrazioni e Dosaggi Disponibili<\/h2>\n<p>MedsBase stocks L-Carnitine in two lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Dosaggio per Flaconcino<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso d'Uso Tipico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Dimensioni della Confezione<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>600 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 dose-titration protocols, in-vitro mitochondrial-function panels, short-cycle in-vivo work, sperm-motility studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 fiale<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>1200 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Extended-cycle or higher-dose protocols \u2014 long-arm metabolic studies, exercise-physiology saturation experiments, multi-cohort work; lowest per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 fiale<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Both strengths are the same chemical form (lyophilized levocarnitine zwitterion, \u226599% HPLC purity). Vial doses are deliberately much larger than the peptide range (5\u201320 mg) because L-carnitine is a small molecule used at gram-level doses \u2014 a 600 mg or 1200 mg vial corresponds roughly to a single intravenous dose in rodent or large-animal protocols. Users should determine specific dose ranges from peer-reviewed literature appropriate to the protocol. <\/p>\n<h2>Confronto \u2014 L-Carnitina vs NAD\u207a<\/h2>\n<p>L-Carnitina e <a href=\"https:\/\/medsbase.com\/it\/nad\/\">NAD\u207a<\/a> are the two non-peptide mitochondrial \/ metabolic support compounds in this catalogue, and they target completely different layers of mitochondrial bioenergetics. L-Carnitine sits on the <em>lato del combustibile<\/em> \u2014 trasporta gli acidi grassi a catena lunga nella matrice per la \u03b2-ossidazione. Il NAD\u207a opera sul <em>lato del trasporto di elettroni<\/em> \u2014 it is the obligate electron acceptor for \u03b2-oxidation, glycolysis, and the TCA cycle, regenerated by Complex I of the electron transport chain. The two compounds are mechanistically complementary, and protocols sometimes combine them to probe upstream-substrate vs downstream-electron-flux contributions to mitochondrial output. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Criterio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">L-Carnitina<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">NAD\u207a<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Classe chimica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Derivato amminoacidico di ammonio quaternario (singolo zwitterione)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Coenzima dinucleotide (adenina + nucleotidi di nicotinamide uniti da difosfato)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Peso molecolare<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">161.20 g\/mol<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">663.43 g\/mol<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Ruolo nei mitocondri<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Trasportatore \u2014 navetta per acidi grassi a catena lunga attraverso la membrana interna<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Accettore di elettroni per \u03b2-ossidazione, glicolisi, ciclo di Krebs; substrato per sirtuine e PARP<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Best-studied studies focus<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ossidazione dei grassi, sensibilit\u00e0 all'insulina, cardiovascolare, motilit\u00e0 spermatica, fisiologia dell'esercizio<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Biologia delle sirtuine, longevit\u00e0, invecchiamento cellulare, regolazione redox dell'asse NAD<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Approvazione FDA<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">S\u00ec \u2014 levocarnitina, per carenza primaria\/secondaria di carnitina (orale e IV)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">No \u2014 compound only<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Biosintesi endogena<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Da L-lisina e L-metionina, nel rene\/fegato\/cervello<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Da triptofano (de novo) o nicotinamide\/niacina (salvaggio)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Stabilit\u00e0 plasmatica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Stabile \u2014 ore di emivita<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Instabile \u2014 emivita di pochi minuti in soluzione; si ossida e degrada rapidamente<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dosaggio tipico<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Centinaia di mg fino a livello di grammo (dose singola nei protocolli su roditori\/animali di grandi dimensioni)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Decine a centinaia di mg (coltura cellulare: concentrazioni \u00b5M)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies focused on long-chain fatty-acid oxidation, cardiovascular metabolic function, insulin sensitivity, or sperm motility, L-Carnitine is the canonical reference compound. For studies focused on sirtuin biology, longevity-axis biochemistry, or NAD-dependent redox regulation, <a href=\"https:\/\/medsbase.com\/it\/nad\/\">NAD\u207a<\/a> \u00e8 lo strumento pi\u00f9 mirato. Vedi anche <a href=\"https:\/\/medsbase.com\/it\/ss-31-elamipretide\/\">SS-31 (Elamipretide)<\/a> for cardiolipin \/ inner-membrane-targeted mitochondrial studies and <a href=\"https:\/\/medsbase.com\/it\/mots-c\/\">MOTS-c<\/a> for mitochondrial-derived peptide-signalling studies. <\/p>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 14px 18px; margin: 18px 0;\"><strong class=\"mb-bac-water-callout\">\ud83d\udca7 Hai bisogno di acqua BAC?<\/strong> La ricostituzione di qualsiasi flaconcino liofilizzato richiede acqua sterile batteriostatica. Abbina questo prodotto al nostro <a href=\"\/it\/bac-water\/\"><strong>BAC Water (Acqua Batteriostatica)<\/strong><\/a> \u2014 flaconcino multidose da 30 mL, conservato con alcool benzilico 0,9%, grado USP.<\/div>\n<h2>Conservazione e ricostituzione<\/h2>\n<p><strong>Prima della ricostituzione:<\/strong> conservare le fiale liofilizzate refrigerate a 2\u20138 \u00b0C nella confezione originale per scorte di lavoro a breve termine. Per lo stoccaggio a lungo termine, congelare le fiale non aperte a \u221220 \u00b0C. La L-Carnitina liofilizzata \u00e8 stabile in frigorifero fino a 36 mesi e a \u221220 \u00b0C fino a 60 mesi \u2014 sostanzialmente pi\u00f9 stabile della maggior parte dei peptidi liofilizzati perch\u00e9 la struttura a piccola molecola non ha legami ammidici o ponti disolfuro da idrolizzare. Il composto \u00e8, tuttavia, <strong>igroscopico<\/strong>, quindi richiudere le fiale prontamente dopo ogni prelievo ed evitare l'esposizione prolungata all'umidit\u00e0 ambientale. <strong>Procedura di ricostituzione:<\/strong> iniettare acqua batteriostatica lungo la parete laterale della fiala (non direttamente sul panetto liofilizzato). Per una fiala da 600 mg, 3,0 mL di acqua batteriostatica producono una concentrazione di lavoro di 200 mg\/mL; 1,2 mL producono una scorta di 500 mg\/mL. Per una fiala da 1200 mg, 6,0 mL producono una scorta di lavoro di 200 mg\/mL; 2,4 mL producono una scorta di 500 mg\/mL. La L-Carnitina si scioglie molto rapidamente con un leggero agitamento \u2014 tipicamente entro 10\u201330 secondi \u2014 perch\u00e9 \u00e8 uno zwitterione piccolo senza struttura ripiegata da disturbare. Una volta ricostituita, conservare la fiala a 2\u20138 \u00b0C e utilizzare entro 30 giorni. Proteggere dalla luce. Scartare se compaiono torbidit\u00e0, particolato o cambiamento di colore. <\/p>\n<h2>Domande frequenti<\/h2>\n<h3>La L-Carnitina \u00e8 un peptide?<\/h3>\n<p>No. La L-Carnitina \u00e8 un derivato aminoacidico a piccola molecola di ammonio quaternario (PM 161,20 g\/mol), <em>not<\/em> a peptide. We stock it in our studies-peptide catalogue alongside <a href=\"https:\/\/medsbase.com\/it\/nad\/\">NAD\u207a<\/a> because it serves a complementary role in mitochondrial \/ metabolic support and is supplied in the same injectable vial format. The spec table Sequence row is marked &#8220;n\/a&#8221; for this reason. <\/p>\n<h3>Qual \u00e8 la differenza tra L-Carnitina e acetil-L-carnitina (ALCAR)?<\/h3>\n<p>Acetyl-L-carnitine is L-carnitine with an acetyl group esterified to the hydroxyl side chain. ALCAR crosses the blood-brain barrier more efficiently and is the form most commonly used in CNS-focused studies (Alzheimer-disease, peripheral neuropathy). The base L-carnitine zwitterion that we supply here is the form used in peripheral metabolic support (cardiovascular, skeletal muscle, sperm motility, dialysis-related deficiency). The two compounds interconvert metabolically through carnitine acetyltransferase. <\/p>\n<h3>Qual \u00e8 la differenza tra L-Carnitina e la DL-carnitina racemica?<\/h3>\n<p>Only the L (3R) enantiomer is biologically active. The D (3S) enantiomer is inactive and is now well-documented to interfere with L-form transport, accumulating in tissue and producing weakness and other adverse effects in long-term high-dose contexts. Pharmaceutical-grade levocarnitine (what we supply) is the enantiomerically pure L-form. The racemic DL-form is obsolete and is no longer used in either clinical or rigorous contexts. <\/p>\n<h3>Why is the dose so much larger than the peptide doses in this catalogue?<\/h3>\n<p>L-Carnitine is a small molecule (MW 161) and is used at gram-level doses \u2014 the body&#8217;s endogenous carnitine pool is approximately 25 g, concentrated in skeletal muscle. Study protocols typically use 100\u2013500 mg\/kg in rodent in-vivo work, which translates to hundreds of milligrams to grams per dose. Compare this to peptides (BPC-157, semaglutide, etc.) where typical doses are 100 \u00b5g to 5 mg per administration \u2014 three to four orders of magnitude smaller, reflecting the different molecular weights and the different receptor \/ mechanism scales. <\/p>\n<h3>What is the TMA \/ TMAO question I see in cardiovascular studies?<\/h3>\n<p>A subset of L-carnitine ingested orally is degraded by gut bacteria to trimethylamine (TMA), which the liver then oxidises to trimethylamine-N-oxide (TMAO). Elevated TMAO levels have been associated in epidemiological studies with adverse cardiovascular events, raising a controversy about whether long-term high-dose oral L-carnitine supplementation may be net-beneficial or net-harmful for cardiovascular endpoints. The question is active and unresolved. Parenteral L-carnitine bypasses the gut-microbial degradation pathway and is not subject to this concern. <\/p>\n<h3>What does CPT-I inhibition mean in metabolic support?<\/h3>\n<p>Carnitine palmitoyltransferase I (CPT-I) is the rate-limiting enzyme for mitochondrial long-chain fatty-acid uptake. Etomoxir is a classical CPT-I inhibitor used to block fat oxidation in study models; it is the pharmacological tool counterpart to the L-carnitine substrate. Study protocols sometimes combine L-carnitine supplementation (substrate side) with CPT-I inhibition (enzymatic side) to dissect substrate-limited vs enzyme-limited fat oxidation in different tissues and conditions. <\/p>\n<h3>Can I combine L-Carnitine with NAD\u207a in the same protocol?<\/h3>\n<p>Yes \u2014 the two compounds target different layers of mitochondrial bioenergetics (substrate transport vs electron transport), and combination is commonly used in studies that aims to probe upstream vs downstream limitations on mitochondrial output. They are chemically stable in solution together. Reconstitute each separately first to establish stability and concentration accuracy, then combine immediately before use rather than co-storing reconstituted vials. <\/p>\n<h3>What route of administration is used in published studies?<\/h3>\n<p>Intravenous and intramuscular routes are most common in pharmacological studies because they bypass the low (~15%) oral bioavailability and the gut-microbial TMA\/TMAO degradation pathway. Subcutaneous administration is used in some rodent protocols. Oral administration is used in pharmacokinetic and nutritional studies where the bioavailability question is itself the studies focus. <!-- medsbase-related-alts-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Navetta mitocondriale per acidi grassi a catena lunga (non un peptide)<br \/>\n\u2705 Substrato del sistema di trasporto CPT-I \/ CACT \/ CPT-II<br \/>\n\u2705 Studiato in modelli di ossidazione dei grassi, sensibilit\u00e0 all'insulina e cardiovascolari<br \/>\n\u2705 Acyl-CoA \/ free-CoA ratio buffer; sperm-motility studies<br \/>\n\u2705 Levocarnitina approvata dalla FDA per carenza di carnitina (orale e endovenosa)<\/p>\n<p><strong>L-Carnitina<\/strong> contiene levocarnitina sintetica.<\/p>","protected":false},"featured_media":71414,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6472,6469,6470,6471],"class_list":["post-71409","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-amino-acid-derivative","product_tag-l-carnitine","product_tag-levocarnitine","product_tag-mitochondrial","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product\/71409","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/comments?post=71409"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/media\/71414"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/media?parent=71409"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product_brand?post=71409"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product_cat?post=71409"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product_tag?post=71409"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}